Saturday 17 October 2026
Export CVRX’s income statement to Excel — free account
CVRx, Inc.
CVRX Healthcare Medical Devices
CVRx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $56.7 million, up 10.4% from fiscal 2024. In the quarter to June 2026, revenue grew 15.6%, EPS grew 7.02%, free cash flow fell 11.2% and total debt rose 18.6%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
1.30
0.09
−6.47%
Follow CVRX
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 3 | 3 | 3 | 2 | 4 |
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | 8.58 | 9.62 | 4.36 | (2.90) | (6.26) |
P/S ratio |
— | 1.25 | 1.25 | 9.72 | 17.12 | 16.10 | 5.58 | 3.27 |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | (38.89) | (11.81) | 19.92 | (0.37) | (8.06) | (9.08) | (15.50) |
Beneish M-Score |
— | — | (1.70) | (1.82) | 4.17 | (1.42) | (3.25) | (3.03) |
P/Operating CF |
— | (1.59) | (1.59) | (18.06) | (35.47) | (80.72) | (35.75) | (18.98) |
P/B ratio |
— | 0.00 | 0.00 | 0.87 | 3.52 | 8.33 | 4.03 | 4.71 |
Price to Tangible BV |
— | 0.00 | 0.00 | 0.87 | 3.52 | 8.33 | 4.03 | 4.71 |
EV/Sales |
— | (2.12) | (2.12) | 0.32 | 12.84 | 14.63 | 4.54 | 2.87 |
EV/EBITDA |
— | 1.11 | 1.11 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | 0.84 | 0.84 | (0.15) | (6.76) | (14.73) | (5.95) | (4.04) |
EV/FCF |
— | 0.81 | 0.81 | (0.14) | (6.65) | (14.51) | (5.75) | (3.98) |
Quick Ratio |
— | 3.07 | 7.57 | 24.48 | 13.81 | 12.48 | 10.70 | 6.49 |
Current Ratio |
— | 3.36 | 8.07 | 25.58 | 15.19 | 14.25 | 12.06 | 7.63 |
Net Debt/EBITDA |
— | (26.95) | 3.57 | 5.56 | 2.36 | 1.45 | 0.97 | 0.52 |
Debt/Assets |
0.00% | 1,027.16% | 29.76% | 0.00% | 5.40% | 25.36% | 36.93% | 47.25% |
Debt/Equity |
— | (1.07) | 0.52 | 0.00 | 0.06 | 0.38 | 0.69 | 1.26 |
Asset Turnover |
— | 0.43 | 0.13 | 0.12 | 0.16 | 0.33 | 0.41 | 0.48 |
Operating CF/Net income |
— | 0.87 | 1.12 | 0.64 | 1.03 | 0.95 | 0.65 | 0.75 |
Capex/Depreciation |
— | 0.00 | (0.86) | (2.98) | (1.57) | (0.87) | (1.66) | (0.58) |
Interest Coverage |
— | (11.85) | (4.66) | (11.70) | (257.74) | (23.96) | (13.53) | (8.80) |
| — | 5.12% | 5.01% | 58.50% | (32.47%) | (44.51%) | (81.58%) | (96.59%) | |
| — | (100.64%) | (30.52%) | (39.64%) | (29.86%) | (34.31%) | (48.23%) | (44.76%) | |
ROIC |
— | 0.00% | 0.00% | (417.55%) | (273.09%) | (184.52%) | (258.29%) | (244.03%) |
Return on Tangible Assets |
— | (71.56%) | (25.23%) | (29.38%) | (35.56%) | (38.87%) | (49.33%) | (58.85%) |
Average Days of Receivables |
— | 41.94 | 77.25 | 71.68 | 89.41 | 70.14 | 65.95 | 68.71 |
Research and Development Expense of Revenue |
— | 138.44% | 105.90% | 57.54% | 44.29% | 29.60% | 21.70% | 19.65% |
Selling, General and Administrative Expense of Revenue |
— | 96.69% | 160.53% | 213.74% | 222.73% | 164.17% | 178.03% | 156.17% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 2.18% | 14.67% | 17.30% | 16.04% | 37.14% | 19.51% |
Graham Net Nets |
— | 1.00 | 1.00 | 1.14 | 0.28 | 0.12 | 0.24 | 0.20 |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | (326.95%) | (326.95%) | (598.67%) | (10.78%) | (6.49%) | (21.23%) | (28.87%) |
Free Cash Flow Yield |
— | (209.17%) | (209.17%) | (22.82%) | (11.28%) | (6.26%) | (14.15%) | (22.00%) |
Revenue per Share |
— | 0.32 | 15.64 | 1.26 | 1.09 | 1.89 | 2.27 | 2.17 |
Operating CF per Share |
— | (0.66) | (41.59) | (2.68) | (2.08) | (1.88) | (1.73) | (1.54) |
Capex per Share |
— | 0.00 | (0.80) | (0.11) | (0.03) | (0.03) | (0.06) | (0.02) |
Free Cash Flow per Share |
— | (0.66) | (42.40) | (2.79) | (2.11) | (1.91) | (1.79) | (1.56) |
Cash per Share |
— | 1.33 | 152.74 | 13.71 | 5.17 | 4.36 | 4.69 | 2.90 |
Shareholders Equity per Share |
— | (14.46) | 94.95 | 14.09 | 5.32 | 3.66 | 3.14 | 1.51 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (14.46) | 94.95 | 14.09 | 5.32 | 3.66 | 3.14 | 1.51 |
Free Cash Flow |
— | (12.78) | (16.41) | (28.91) | (43.36) | (39.61) | (40.50) | (40.75) |
Working Capital |
— | 20.29 | 56.36 | 145.19 | 114.79 | 104.23 | 119.05 | 88.33 |
Capital Expenditures |
— | (0.11) | (0.31) | (1.18) | (0.68) | (0.59) | (1.36) | (0.58) |
Net Current Asset Value |
— | (279.24) | 36.31 | 144.51 | 107.12 | 72.81 | 67.45 | 36.18 |
EV/EBIT |
— | 1.09 | 1.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | 0.00 | 0.05 | 0.09 | 0.03 | 0.02 | 0.03 | 0.01 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||
Depreciation/Fixed assets |
— | 0.32 | 0.88 | 0.28 | 0.26 | 0.38 | 0.33 | 0.44 |
Cash ROIC |
— | (27.99%) | (14.25%) | (10.04%) | (19.52%) | (20.24%) | (17.90%) | (24.77%) |
Accounts Receivable Turnover |
— | 6.26 | 6.05 | 6.79 | 5.57 | 6.02 | 6.10 | 5.68 |
Accounts Payable Turnover |
— | 3.78 | 3.13 | 7.33 | 4.49 | 3.47 | 3.73 | 2.59 |
Inventory Turnover |
— | 0.64 | 0.53 | 1.01 | 0.92 | 0.70 | 0.72 | 0.68 |
Average Days of Payables |
— | 91.72 | 122.43 | 51.14 | 125.51 | 109.92 | 113.08 | 168.34 |
Days of Inventory on Hand |
— | 434.89 | 847.36 | 389.07 | 507.96 | 640.79 | 530.24 | 536.02 |
Average Receivables |
— | 1.00 | 1.00 | 1.92 | 4.03 | 6.53 | 8.41 | 9.97 |
Average Payables |
— | 0.46 | 0.46 | 0.50 | 1.11 | 1.80 | 2.23 | 3.21 |
Average Inventory |
— | 2.71 | 2.71 | 3.61 | 5.42 | 8.97 | 11.55 | 12.16 |
Average Assets |
— | 14.55 | 46.94 | 108.66 | 138.74 | 120.08 | 124.32 | 119.10 |
Average Common Equity |
— | (286.14) | (286.14) | (73.64) | 127.57 | 92.56 | 73.50 | 55.19 |
Columns are period end dates